The Psychedelic Renaissance: Pharmacology and History, Neuroscience and Clinical Efficacy

Thank you

This live web event has ended. Thank you for attending.

Description

The IASP 2022 World Congress on Pain took place from 19-23 September 2022, in Toronto, Canada. As a part of the World Congress Virtual Program, IASP will host eleven 90-minute Post-Congress webinars. These webinars will provide registrants with practical reviews of current research and therapies surrounding pain and will feature live Q&A sessions with international experts in pain management and pain research. The Virtual Program is available to all IASP 2022 World Congress on Pain registered attendees (i.e., both in-person and virtual registrants).

There are three pricing tiers for this Post-Congress webinar:
1) FREE to all IASP 2022 World Congress on Pain registered attendees (registrants must enter the promo code provided via email during checkout).
2) $5.00 USD for all IASP members that did not register to attend the IASP 2022 World Congress on Pain.
3) $25.00 USD for all IASP non-members.

The Psychedelic Renaissance: Pharmacology and History, Neuroscience and Clinical Efficacy

This first Post-Congress webinar introduces the audience to the current knowledge of this emerging field and its potential relevance to pain management.

The first presenter, Kirran Ahmad, MD, will introduce background information on classical psychedelics with their ethnopharmacology, recent history, legal aspects, and pharmacology.

The second presenter, Gabriella Gobbi, MD, PhD, will discuss psychedelic mechanisms of action as modulators of neurotransmitter systems, neuroplastic agents, immune modulation, anti-inflammatory effects, activity and connectivity of neural networks, and altered functional processing.

The third presenter, Emmanuelle Schindler, MD, PhD, will then review the investigational non-invasive measuring techniques and clinical efficacy of these agents in relation to headache disorders, other chronic pain conditions, suffering in terminal illness, depression, PTSD, and addiction.

There will be a live Q&A session following each presentation.

Contributors:
-- Kirran Ahmad, MD, Imperial College London, UK
Introduction to Psychedelics
-- Gabriella Gobbi, MD, PhD, McGill University, Montreal, Canada
The Neuroscience of Psychedelics
-- Emmanuelle Schindler MD, PhD, Yale School of Medicine; Veterans Affairs Connecticut Health System, USA
The Clinical Efficacy of Psychedelics
-- John Akers, MD, Royal Perth Hospital, Australia (moderator)

Contributors

Kirran Ahmad, MD

Kirran Ahmad, MD, joined the Centre for Psychedelic Research at Imperial College London, UK, in 2021 as a Clinical Research Fellow. Kirran is a Senior Anaesthetic Registrar at the NHS Barts and Royal London Hospital Trust with a specialist interest in chronic pain. She obtained her Bachelor of Medicine from the University of Nottingham, UK, in 2009 and the Fellowship of the Royal College of Anaesthetists in 2016. At Imperial, Kirran forms part of the team investigating the role of psilocybin in fibromyalgia.
Gabriella Gobbi, MD, PhD

Gabriella Gobbi, MD, PhD, is a Professor in the Department of Psychiatry at McGill University, Montreal, Canada. She is interested in understanding the causes of mental diseases and discovering new treatments. In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabinoids) in the cure of mental diseases. Her lab also studies the action mechanism of hallucinogens and their potential therapeutic effects. In addition, her laboratory examines the effect of melatonin in mood, anxiety, and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, and other neuropsychiatric conditions. The laboratory approach spans from bench to bedside, bridging the gaps between fundamental and clinical research.
Emmanuelle Schindler, MD, PhD

Emmanuelle Schindler, MD, PhD, is an Assistant Professor of Neurology at Yale School of Medicine, Connecticut, USA and the Medical Director of the Headache Center of Excellence at VA Connecticut Healthcare System. She is a board-certified Neurologist and Headache Medicine specialist with a particular interest in cluster headache. Among her efforts to optimize the management of this and other headache disorders, Dr. Schindler has developed and executed the first controlled trials investigating the safety and efficacy of psilocybin in cluster, migraine, and post-traumatic headache. Previously, she studied the neuropharmacology of psychedelics and other serotonergic compounds in the context of receptor binding and intracellular signaling at Drexel University College of Medicine, Philadelphia, USA, where she achieved her PhD. Her neuropharmacology background frames her endeavor to investigate the potential for psychedelics to serve as safe and effective therapeutic agents in headache disorders. Currently, she seeks to identify the source of sustained reductions in headache burden after limited dosing of psychedelic and related compounds, considering several neurobiological systems involved in both headache pathology and the known actions of psychedelic compounds.
John Akers, MD

John Akers, MD, is a staff Anesthetist/Anesthesiologist and Pain Physician at Royal Perth Hospital, Australia’s second largest trauma center. He has worked with ketamine in the perioperative period for almost 40 years and in pain medicine for almost 30 years. He was involved with novel approaches to its delivery while managing burns victims from the Bali bombing 20 years ago. With his colleagues from psychology in the pain clinic he is examining the role of ketamine and psychedelics in nociplastic pain states and maladaptive pain behaviors. He is grateful for the IASP to allow this project of disseminating the science of psychedelics to the membership.